Abstract:(1) Background: Brown adipose tissue (BAT) is responsible for non-shivering thermogenesis, and its activation has become a new object as both a determinant of metabolic health and a target for therapy. This study aimed to identify the relationships between the presence of BAT, parameters that characterize metabolic health (glucose, lipids, blood pressure (BP)), and the dynamics of body mass index (BMI) during weight-reducing therapy. (2) Methods: The study included 72 patients with obesity. We investigated metabolic parameters, anthropometric parameters, and BP. Dual-energy X-ray absorptiometry (DXA) and positron emission tomography and computed tomography (PET/CT) imaging with 18F-fluorodeoxyglucose (18F-FDG) were performed. (3) Results: Before weight-reducing therapy, BAT was revealed only in 19% patients with obesity. The presence of BAT was associated with a lower risk of metabolic deviations that characterize metabolic syndrome: shorter waist circumference (WC) (p = 0.02) and lower levels of glucose (p = 0.03) and triglycerides (p = 0.03). Thereafter, patients were divided into four groups according to the type of therapy (only lifestyle modification or with Liraglutide or Reduxin or Reduxin Forte). We did not find a relationship between the presence of BAT and response to therapy: percent weight reduction was 10.4% in patients with BAT and 8.5% in patients without BAT (p = 0.78) during six months of therapy. But we noted a significant positive correlation between the volume of BAT and the effectiveness of weight loss at 3 months (r = 0.52, p = 0.016). The dynamic analysis of BAT after 6 months of therapy showed a significant increase in the volume of cold-induced metabolically active BAT, as determined by PET/CT with 18F-FDG in the Liraglutide group (p = 0.04) and an increase in the activity of BAT standardized uptake value (SUV mean and SUV max) in the Reduxin (p = 0.02; p = 0.01, respectively) and Liraglutide groups (p = 0.02 in both settings). (4) Conclusions: The presence of brown adipose tissue is associated with a lower risk of metabolic abnormalities. In general, our study demonstrated that well-established drugs in the treatment of obesity (Liraglutide and Reduxin) have one more mechanism for implementing their effects. These drugs have the ability to increase the activity of BAT. A significant positive relationship between the total volume of BAT and the percentage of weight loss may further determine the priority mechanism of the weight-reducing effect of these medicaments.

Brown Adipose Tissue Prevalence Is Lower in Obesity but Its Metabolic Activity Is Intact

Differences in Sympathetic Nervous Stimulation of Brown Adipose Tissue Between the Young and Old, and the Lean and Obese

Brown Adipose Tissue Activation is Inversely Related to Central Obesity and Metabolic Parameters in Adult Human

Brown adipose tissue is associated with healthier body fat distribution and metabolic benefits independent of regional adiposity

Brown adipose tissue is associated with cardiometabolic health

Differences in the Metabolic Status of Healthy Adults with and Without Active Brown Adipose Tissue

Relation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease

Role of Brown Adipose Tissue in Metabolic Health and Efficacy of Drug Treatment for Obesity

Brown Adipose Tissue Energy Metabolism in Humans

Brown Adipose Tissue and Regulation of Human Body Weight

Impact of brown adipose tissue on body fatness and glucose metabolism in healthy humans

Adults with metabolically healthy overweight or obesity present more brown adipose tissue and higher thermogenesis than their metabolically unhealthy counterparts

A larger brown fat volume and lower radiodensity are related to a greater cardiometabolic risk, especially in young men

Dietary Intake Is Similar Among Adult Men with Different Levels of Cold-Induced Brown Adipose Tissue Activation

Human Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues

Weighing in on the role of brown adipose tissue for treatment of obesity

[Brown Adipose Tissue in Human and Its Potential Physiological Significance].

Brown Adipose Tissue: Activation and Metabolism in Humans

Brown Adipose Tissue In Humans Is Activated By Elevated Plasma Catecholamines Levels And Is Inversely Related To Central Obesity

Econutrition, Brown And Beige Fat Tissue And Obesity

Brown fat tissue imaging with 18F-FDG PET/CT and its relationship with central obesity and metabolic parameters in adult human